65,437 trials
Lung Cancer, Non-Small Cell
Primary: Progression-free Survival (PFS) — 25.0; 22.9 weeks — p=0.2647
Jaw, Edentulous, Partially
Primary: Implant Survival Rate — 89.9 Percentage of implants
Anemia, Sickle Cell
Primary: Area Under the Plasma Concentration-Time Curve (AUC) From Time of Dosing Through the Sampling Time of the Last Quantifiable Concentration [AUC(0-tlast)] for Prasugrel's…
Influenza
Primary: Geometric Mean of Haemagglutination Inhibiting (HI) Antibodies Titers Against the Three Strains. — 46.0; 45.8; 320.9; 329.4 Titers
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms
Primary: Serologic Response (Change in CA125 Level) — 2 participants
Congenital Heart Disease
Primary: Number of Subjects Reporting Adverse Events Through Study Day 150 — 575; 566 participants
Coronary Artery Disease
Primary: Target Lesion Failure (TLF) — 3.2 percentage of participants — p=<0.0001
Pancreatic Cancer
Primary: Median Overall Survival (OS) — 42 months
Fibromyalgia
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 102; 3 Participants
Epilepsy
Primary: Average Annualized Costs — 1352; 462; 1357; 1050 United States dollars — p=<0.0001
Major Depressive Disorder
Primary: Change From Baseline in the Brief Pain Inventory-Short Form (BPI-SF) Average Pain Score During the 8-Week Treatment Period — -1.66; -1.17 units on a scale — p=<0.001
Coronary Artery Disease
Primary: Target Lesion Failure (TLF) — 2.4 percentage of participants — p=<0.0001
Acne Vulgaris
Primary: Erythema (Redness) — 0.94; 1.05; 1.42; 1.24 units on a scale — p=>0.05
Lymphoma
Primary: Disease-free Survival (DFS) — 11.33; 9.635 months
Gastric Ulcer · Duodenal Ulcer
Primary: Percentage of Participants Who Experienced the Occurence of Peptic Ulcer(s). — 1.35; 1; 6.58 percentage of participants